Impact of neoadjuvant targeted therapy on perioperative complications in patients with localized reno-cellular cancer

Keywords: reno-cellular cancer; neoadjuvant targeted therapy; perioperative complications.

Abstract

Objective. To study the efficacy of neoadjuvant targeted therapy in treatment of localized reno-cellular cancer and to determine its impact on the perioperative complications rate.

Materials and methods. There are presented the results of randomized investigation, conducted in 152 patients with localized reno-cellular cancer. Into the main group 75 (49.3%) patients were included, to whom neoadjuvant targeted therapy and operative treatment were conducted, and into the control group - 77 (50.7%) patients, to whom operative treatment was performed only. The groups were randomized in accordance to the main clinical parameters. Efficacy of treatment was estimated in accordance to RECIST 1.1 scale, complications – in accordance to Clavien-Dindo classification.

Results. Neoadjuvant targeted therapy did not influence the operation duration: (95 ± 19) min – while conduction of targeted therapy and (108 ± 53) min – without conduction of targeted therapy, and duration of postoperative treatment: (5.6 ± 1.9) and (5.2 ± 2.3) bed-days, accordingly. The intraoperative blood loss volume in renal resection of the patients’ main group in comparison with patients of a control group have constituted (407 ± 224) and (317 ± 210) ml accordingly (p=0.013). Neoadjuvant targeted therapy did not influence the perioperative complications rate, which have occurred in 7 (9.3%) patients of the main and in 8 (10.7%) patients of a control group, and their severity did not exceed 3 degrees in accordance to Clavien-Dindo classification.

Conclusion. Neoadjuvant targeted therapy do not increase the operation duration, the perioperative complications rate and postoperative treatment time, but increases the blood loss volume while performance of renal resection (p=0.013).

Author Biographies

O. A. Voylenko, National Cancer Institute, Kyiv

Voylenko Oleg A. - MD, PhD (Med), Senior Researcher
Department of Plastic and Reconstructive Oncological Urology,
National Cancer Institute,
33/43 Lomonosova Str., 03022, Kyiv, Ukraine
+38 050 501 19 03
voilenko@rambler.ru
orcid.org/0000-0003-3781-3622

O. E. Stakhovskyi, National Cancer Institute, Kyiv

Stakhovskyi Oleksandr E. - MD, PhD (Med), Senior Researcher
Department of Plastic and Reconstructive Oncological Urology,
National Cancer Institute,
33/43 Lomonosova Str., 03022, Kyiv, Ukraine
+38 050 381 72 17
stakhovsky9@gmail.com
orcid.org/0000-0002-0030-5459

O. A. Kononenko, National Cancer Institute, Kyiv

Kononenko Oleksii A. - MD, PhD (Med), Researcher
Department of Plastic and Reconstructive Oncological Urology,
National Cancer Institute,
33/43 Lomonosova Str., 03022, Kyiv, Ukraine
+38 097 269 32 35
kononenko_ol@ukr.net
orcid.org/0000-0002-7081-5964

S. L. Semko, National Cancer Institute, Kyiv

Semko Sofiya L. - MD, Urologist
Department of Plastic and Reconstructive Oncological Urology,
National Cancer Institute,
33/43 Lomonosova Str., 03022, Kyiv, Ukraine
+38 063 252 65 36
semkosofiya@gmail.com
orcid.org/0000-0002-1657-5752

M. V. Pikul, National Cancer Institute, Kyiv

Pikul Maksym V. - MD, Urologist
Department of Plastic and Reconstructive Oncological Urology,
National Cancer Institute,
33/43 Lomonosova Str., 03022, Kyiv, Ukraine
+38 093205 06 96
urogenetics@gmail.com
orcid.org/0000-0003-1590-235X

Yu. V. Vitruk, National Cancer Institute, Kyiv

Vitruk Iurii V. - MD, PhD (Med), Senior Researcher
Department of Plastic and Reconstructive Oncological Urology,
National Cancer Institute,
33/43 Lomonosova Str., 03022, Kyiv, Ukraine
+38 050 673 20 82
uvitruk@ukr.net
orcid.org/0000-0003-3466-0552

E. O. Stakhovsky , National Cancer Institute, Kyiv

Stakhovsky Eduard O. - MD, DSci(Med), Professor,
Head of Department of Plastic and Reconstructive Oncological Urology,
National Cancer Institute,
33/43 Lomonosova Str., 03022, Kyiv, Ukraine
+38 067 236 51 75
estakhovsky@yahoo.com
orcid.org/0000-0001-5677-8768

References

Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, et al. EAU Renal Cell Carcinoma Guideline. Eur Urol, 2007;51(6):1502–10. doi: 10.1016/j.eururo.2007.03.035.

Smith DH, Thorp ML, Gurwitz JH, McManus DD, Goldberg RJ, Allen LA, et al. Chronic Kidney Disease and Outcomes in Heart Failure With Preserved Versus Reduced Ejection Fraction. Circ Cardiovasc Qual Outcomes. 2013;6(3):333–42. doi: 10.1161/CIRCOUTCOMES.113.000221.

NCCN Guidelines Version 2.2019. Kidney Cancer. Available from: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.

Abu-Ghanem Y, Dabestani S, Fernández-Pello Montes S, Hofmann F, Kuusk T, Tahbaz R. Renal Cell Carcinoma. In: EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona 2019. ISBN 978-94-92671-04-2. EAU Guidelines Office, Arnhem, The Netherlands. Available from: http://uroweb.org/guidelines/compilations-of-all-guidelines/.

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-305. doi:10.1056/NEJMoa041031.

Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int. 2011;80(6):572-86. doi:10.1038/ki.2011.223.

Silberstein JL, Millard F, Mehrazin R, Kopp R, Bazzi W, DiBlasio CJ, et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron- sparing surgery. BJU Int. 2010;106:1270–6. doi: 10.1111/j.1464-410X.2010.09357.x.

Rini BI, Plimack ER, Takagi T, Elson P, Wood LS, Dreicer R, et al. A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J Urol. 2015;194(2):297–303. doi: 10.1016/j.juro.2015.03.096.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.

Dindo D, Demartines N, Clavien PA. Classification of Surgical Complications. A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey. Ann Surg. 2004; 240(2):205–13. PMID 15273542.

Tang T, Jiang H, Yu Y, He F, Ji SZ, Liu YY, et al. A new method of wound treatment: targeted therapy of skin wounds with reactive oxygen species-responsive nanoparticles containing SDF-1α. Int J Nanomedicine. 2015;10:6571-85. doi: 10.2147/IJN.S88384.

Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nat Rev Urol. 2010;7(6):327-38. doi: 10.1038/nrurol.2010.57.

Bindayi A, Hamilton ZA, McDonald ML, Yim K, Millard F, McKay RR, et al. Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. Urol Oncol. 2018;36(1):31-7. doi: 10.1016/j.urolonc.2017.07.015.

Porta C, Paglino C, Grünwald V. Sunitinib re-challenge in advanced renal-cell carcinoma. Br J Cancer. 2014;111(6):1047-53. doi: 10.1038/bjc.2014.214.

Hellenthal NJ, Underwood W, Penetrante R, Litwin A, Zhang S, Wilding GE, et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol. 2010;184(3):859-64. doi: 10.1016/j.juro.2010.05.041.

Lane BR, Derweesh IH, Kim HL, O'Malley R, Klink J, Ercole CE, et al. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. Urol Oncol. 2015;33(3):112.e15-21. doi: 10.1016/j.urolonc.2014.11.009.

Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol. 2009;181(2):518-23. doi: 10.1016/j.juro.2008.10.001.

Powles T, Kayani I, Blank C, Chowdhury S, Horenblas S, Peters J, et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol. 2011;22(5):1041-7. doi: 10.1093/annonc/mdq564.

Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, et al. Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2009;27(25):4076-81. doi: 10.1200/JCO.2008.21.3660.

Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol. 2016;69(4):660-73. doi: 10.1016/j.eururo.2015.07.072.

Published
2020-05-26
How to Cite
Voylenko, O. A., Stakhovskyi, O. E., Kononenko, O. A., Semko, S. L., Pikul, M. V., Vitruk, Y. V., & Stakhovsky , E. O. (2020). Impact of neoadjuvant targeted therapy on perioperative complications in patients with localized reno-cellular cancer. Klinicheskaia Khirurgiia, 87(1-2), 53-59. https://doi.org/10.26779/2522-1396.2020.1-2.53
Section
General Problems of Surgery

Most read articles by the same author(s)